Blood–Brain Barrier Permeability and Brain Uptake Mechanism of Kainic Acid and Dihydrokainic Acid

Neurochemical Research

Volumn 40, Issue 3, 2015, Pages 542-549

  Gynther, Mikko ^a,b   Petsalo, Aleksanteri ^b   Hansen, Steen H ^a   Bunch, Lennart ^a   Pickering, Darryl S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Blood brain barrier permeability; Dihydrokainic acid; Kainic acid

Indexed keywords

DIHYDROKAINIC ACID; KAINIC ACID;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; BRAIN PERFUSION; BRAIN UPTAKE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG PROTEIN BINDING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; QUALITY CONTROL; RAT; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; UNBOUND FRACTION; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; ION TRANSPORT; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; ION TRANSPORT; KAINIC ACID; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84925536100     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1499-4     Document Type: Article

References (27)

1. Huneau C, Benquet P, Dieuset G, Biraben A, Martin B, Wendling F (2013) Shape features of epileptic spikes are a marker of epileptogenesis in mice. Epilepsia 54:2219–2227. doi:10.1111/epi.12406
2. Vivash L, Gregoire MC, Bouilleret V, Berard A, Wimberley C, Binns D, Roselt P, Katsifis A, Myers DE, Hicks RJ, O’Brien TJ, Dedeurwaerdere S (2014) In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy. PLoS One 9:e86722. doi:10.1371/journal.pone.0086722
3. Luquin MR, Saldise L, Guillen J, Belzunegui S, San Sebastian W, Izal A, Garrido P, Vazquez M (2006) Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in parkinson’s disease? Exp Neurol 201:407–415. doi:10.1016/j.expneurol.2006.04.033
4. Miller BR, Dorner JL, Bunner KD, Gaither TW, Klein EL, Barton SJ, Rebec GV (2012) Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington’s disease. J Neurochem 121:629–638. doi:10.1111/j.1471-4159.2012.07691.x
5. Ramirez C, Tercero I, Pineda A, Burgos JS (2011) Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J Alzheimer’s Dis 24:161–174. doi:10.3233/JAD-2010-101653
6. Bunch L, Krogsgaard-Larsen P (2009) Subtype selective kainic acid receptor agonists: discovery and approaches to rational design. Med Res Rev 29:3–28
7. Bunch L, Nielsen B, Jensen AA, Brauner-Osborne H (2006) Rational design and enantioselective synthesis of (1R,4S,5R,6S)-3-azabicyclo [3.3.0] octane-4, 6-dicarboxylic acid a novel inhibitor at human glutamate transporter subtypes 1, 2, and 3. J Med Chem 49:172–178. doi:10.1021/jm0508336
8. Larsen AM, Venskutonyte R, Valades EA, Nielsen B, Pickering DS, Bunch L (2011) Discovery of a new class of ionotropic glutamate receptor antagonists by the rational design of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid. ACS Chem Neurosci 2:107–114. doi:10.1021/cn100093f
9. Juknaite L, Venskutonyte R, Assaf Z, Faure S, Gefflaut T, Aitken DJ, Nielsen B, Gajhede M, Kastrup JS, Bunch L, Frydenvang K, Pickering DS (2012) Pharmacological and structural characterization of conformationally restricted (S)-glutamate analogues at ionotropic glutamate receptors. J Struct Biol 180:39–46. doi:10.1016/j.jsb.2012.07.001
10. Battaglia A, Bertoluzza A, Calbucci F, Eusebi V, Giorgianni P, Ricci R, Tosi R, Tugnoli V (1999) High-performance liquid chromatographic analysis of physiological amino acids in human brain tumors by pre-column derivatization with phenylisothiocyanate. J Chromatogr B Biomed Sci Appl 730:81–93
11. Zhang X, Zhao T, Cheng T, Liu X, Zhang H (2012) Rapid resolution chromatography (RRLC) analysis of amino acids using pre-column derivatization. J Chromatogr B 906:91–95
12. Gynther M, Laine K, Ropponen J, Leppanen J, Mannila A, Nevalainen T, Savolainen J, Jarvinen T, Rautio J (2008) Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 51:932–936. doi:10.1021/jm701175d
13. Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705. doi:10.1111/j.1476-5381.2009.00430
14. Smith QR (2000) Transport of glutamate and other amino acids at the blood–brain barrier. J Nutr 130:1016S–1022S
15. Hawkins RA (2009) The blood–brain barrier and glutamate. Am J Clin Nutr 90:867S–874S. doi:10.3945/ajcn.2009.27462BB
16. Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K (1988) Structural and functional variations in capillary systems within the brain. Ann N Y Acad Sci 529:21–30. doi:10.1111/j.1749-6632.1988.tb51416
17. Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–338. doi:10.1002/bdd.325
18. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205–213. doi:10.1124/jpet.107.121525
19. Maucher Fuquay J, Muha N, Wang Z, Ramsdell JS (2012) Elimination kinetics of domoic acid from the brain and cerebrospinal fluid of the pregnant rat. Chem Res Toxicol 25:2805–2809
20. Smith QR (2000) Transport of glutamate and other amino acids at the blood–brain barrier. J Nutr 130:1016S–1022S
21. Ronaldson PT, Davis TP (2013) Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacol Rev 65:291–314
22. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25:1737–1750
23. Stain-Texier F, Boschi G, Sandouk P, Scherrmann JM (1999) Elevated concentrations of morphine 6-beta-d-glucuronide in brain extracellular fluid despite low blood–brain barrier permeability. Br J Pharmacol 128:917–924. doi:10.1038/sj.bjp.0702873
24. van Vliet EA, Otte WM, Gorter JA, Dijkhuizen RM, Wadman WJ (2014) Longitudinal assessment of blood–brain barrier leakage during epileptogenesis in rats. A quantitative MRI study. Neurobiol Dis 63:74–84
25. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H (2008) Seizure-induced up-regulation of P-glycoprotein at the blood–brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 73:1444–1453
26. Loscher W, Potschka H (2005) Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86–98
27. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029–1037